With record-breaking revenues and profits accruing on the back of its COVID-19 products, Pfizer is planning a big spend on business development – but chief executive Albert Bourla says the
Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection
Drugmakers Pfizer and Flynn Pharma have been fined £70 million ($84 million) by the UK Competition and Markets Authority (CMA) for overcharging the NHS for a widely-used epilepsy drug.
AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the EU as it tries to catch up with main rivals Pfizer/BioHaven and their rece
